Truist lowered the firm’s price target on Bristol Myers to $62 from $64 and keeps a Buy rating on the shares after the company reported “strong” Q2 results. The firm said it sees Bristol Myers executing on multiple fronts and see a path forward for growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
Questions or Comments about the article? Write to editor@tipranks.com